BCBS Massachusetts

Does BCBS Massachusetts cover Wegovy?

Quick answer · Weight Loss

BCBS Massachusetts covers Wegovy for weight loss with prior authorization on Employer / Commercial Insurance.

  • Employer / Commercial Insurance: Covered (preferred drug). BMI of 30 or higher

Last verified June 2, 2026. Policy effective May 1, 2026. Source: 572%20GLP-1%20and%20GLP-1%20-%20GIP%20Agonist%20Drugs%20for%20Anti-Obesity%20Management%20and%20Other%20Non-Obesity%20Conditions.pdf. How we verify this data →

Check your card for your exact plan →

Wegovy for Weight Loss

What BCBS Massachusetts requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered (preferred drug)

What you need to qualify

  • BMI of 30 or higher
  • BMI of 27 or higher with a weight-related condition (HTN, dyslipidemia, and T2DM)
  • BMI at or above the 95th percentile for age and sex
  • 6 months of a documented diet and exercise program

Qualification pathways

You can qualify through any one of these.

Adult obesity - BMI >= 30

All of:

  • Adult patient with initial BMI >= 30 kg/m2
  • 6-month trial of comprehensive weight loss plan (reduced calorie diet, increased physical activity, behavioral modifications) prior to initiation
  • Member will use medication as adjunct to comprehensive weight management plan

Adult obesity - BMI >= 27 with comorbidity

All of:

  • Adult patient with initial BMI >= 27 kg/m2
  • At least one weight-related comorbid condition (hypertension, dyslipidemia, type 2 diabetes)
  • 6-month trial of comprehensive weight loss plan (reduced calorie diet, increased physical activity, behavioral modifications) prior to initiation
  • Member will use medication as adjunct to comprehensive weight management plan

Pediatric obesity (subcutaneous Wegovy only, ages 12-17)

All of:

  • Patient is 12 through 17 years of age
  • Initial BMI at 95th percentile or greater standardized for age and gender
  • Documentation includes baseline BMI, baseline weight, and BMI percentile
  • 6-month trial of comprehensive weight loss plan (reduced calorie diet, increased physical activity, behavioral modifications) prior to initiation
  • Member will use medication as adjunct to comprehensive weight management plan

Documentation to bring

  • Baseline BMI documentation
  • For adults: BMI >= 30 kg/m2 OR BMI >= 27 kg/m2 with documentation of at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes)
  • For pediatric patients (subcutaneous Wegovy only): baseline BMI, baseline weight, and BMI percentile documenting >= 95th percentile for age and sex
  • Physician attestation or documentation of completed 6-month comprehensive weight loss program (reduced calorie diet, increased physical activity, behavioral modifications) prior to initiation
  • Physician attestation that member will use medication as adjunct to comprehensive weight management plan
  • Chart notes or lab results supporting medical necessity
  • For continuation: documentation of weight loss >= 5% of baseline body weight within first 16 weeks OR continued weight loss OR maintained plateau weight
  • For continuation: documentation of adherence to and tolerance of recommended maintenance dose for at least 3 consecutive months
  • For continuation: documentation of ongoing comprehensive weight management plan

Quantity limits

  • all strengths — 1-month supply (28 to 30 days); 75% of days must be exhausted before refill

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 12 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight, Must meet ONE of: (a) documented weight loss of at least 5% of baseline body weight after first 16 weeks of treatment; OR (b) demonstrated continued weight loss; OR (c) maintaining plateau weight achieved with diet/exercise. Patient must also be adherent and tolerating recommended maintenance dose for at least 3 consecutive months, and continue with comprehensive weight management plan, and staying on a maintenance dose of at least 1.7 mg. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Mail order pharmacy benefit excluded
  • Members with BCBSMA Focused Formulary: GLP-1/GLP-1/GIP medications are not a covered benefit effective 1/1/2026
  • Wegovy HD (high dose) and Wegovy oral tablet are only FDA approved for adults — pediatric weight loss indication applies to subcutaneous Wegovy only
  • Requests based exclusively on use of samples will not meet coverage criteria

Policy note: Wegovy injection maintenance doses for adults include 1.7 mg, 2.4 mg, or 7.2 mg; for patients 12-17 years include 1.7 mg or 2.4 mg. Wegovy oral tablet maintenance dose is 25 mg. Wegovy HD is NOT FDA approved for MASH or CV risk reduction. Policy applies to Commercial members (HMO/POS, PPO/EPO, Indemnity, MEDEX with Rx, Managed Blue for Seniors) but NOT Medicare Advantage. All GLP-1 prescriptions excluded from mail order pharmacy benefit. For non-covered medications, member must have had previous treatment failure with or contraindication to at least two covered formulary alternatives.

Policy effective May 1, 2026 · verified June 2, 2026 · source: 572%20GLP-1%20and%20GLP-1%20-%20GIP%20Agonist%20Drugs%20for%20Anti-Obesity%20Management%20and%20Other%20Non-Obesity%20Conditions.pdf

Wegovy for Heart Disease Risk Reduction

What BCBS Massachusetts requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered (preferred drug)

What you need to qualify

  • Age 45 and older
  • BMI of 27 or higher
  • Established cardiovascular disease (MI, stroke, and PAD)
  • On guideline-directed medical therapy (antiplatelet_agent, aspirin, P2Y12_inhibitor, clopidogrel, prasugrel, statin, ezetimibe, fibrate, PCSK9_inhibitor, beta_blocker, ACE_inhibitor, and ARB)

Qualification pathways

You can qualify through any one of these.

CV risk reduction - MACE prevention

All of:

  • Patient is 45 years of age or older
  • BMI > 27 kg/m2
  • Established cardiovascular disease (prior MI, prior stroke, or symptomatic PAD)
  • Receiving Standard of Care (SOC) treatment appropriate for their CV condition
  • Patient is NOT NYHA class IV heart failure

Plus any one of:

  • Prior MI
  • Prior stroke
  • Symptomatic PAD with current intermittent claudication and ABI < 0.85 at rest
  • Prior peripheral arterial revascularization procedure
  • Prior amputation due to ASCVD

Documentation to bring

  • Documentation that patient is 45 years of age or older
  • Documentation of BMI > 27 kg/m2
  • Documentation of qualifying established cardiovascular disease event: prior MI, prior stroke, or symptomatic PAD (with ABI < 0.85, prior peripheral arterial revascularization, or prior amputation due to ASCVD)
  • Documentation of current Standard of Care (SOC) treatment including examples from: antiplatelet agents (aspirin or P2Y12 inhibitor), lipid-lowering drugs (statin, ezetimibe, fibrate, or PCSK9 inhibitor), antihypertensives (beta blocker, ACE-I, ARB)
  • Documentation confirming patient is NOT NYHA class IV heart failure
  • For continuation: claims records demonstrating > 80% fill rate
  • For continuation: documentation that patient has not developed Type 2 Diabetes or NYHA class IV heart failure
  • For continuation: documentation of ongoing SOC therapies for CVD
  • For continuation: documentation of FDA approved maintenance dose (injection 1.7 or 2.4 mg, or oral tablet 25 mg)

Quantity limits

  • all strengths — 1-month supply (28 to 30 days); 75% of days must be exhausted before refill

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 12 months
  • To renew, the plan looks for Individual must continue to meet initial approval criteria AND remain adherent (>80% fill rate per claims records) AND not have developed Type 2 Diabetes or NYHA class IV heart failure AND remain on Standard of Care therapies for CVD AND be on FDA approved maintenance dose (Wegovy injection 1.7 or 2.4 mg; Wegovy oral tablet 25 mg). Note: initial CV criteria (age >= 45, established CVD, BMI > 27, SOC treatment) are re-verified at continuation per policy language and staying on a maintenance dose of at least 1.7 mg.

Not covered when

  • NYHA class IV heart failure
  • Wegovy HD is NOT FDA approved for CV risk reduction (MACE)
  • Mail order pharmacy benefit excluded
  • Members with BCBSMA Focused Formulary: not a covered benefit effective 1/1/2026
  • Development of Type 2 Diabetes during treatment is a disqualifier for continuation
  • Requests based exclusively on use of samples will not meet coverage criteria

Policy note: Policy requires SOC treatment; prescriber must provide examples of all applicable SOC medications. Symptomatic PAD must be evidenced by ABI < 0.85 at rest, prior peripheral arterial revascularization procedure, or prior amputation due to ASCVD. Wegovy HD is explicitly excluded from the CV risk reduction indication. Oral Wegovy is included for CV risk reduction per 1/8/2026 update. Continuation requires patient has NOT developed T2D (development of T2D disqualifies continuation for this indication).

Policy effective May 1, 2026 · verified June 2, 2026 · source: 572%20GLP-1%20and%20GLP-1%20-%20GIP%20Agonist%20Drugs%20for%20Anti-Obesity%20Management%20and%20Other%20Non-Obesity%20Conditions.pdf

Wegovy for Liver Disease (MASH)

What BCBS Massachusetts requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered (preferred drug)

What you need to qualify

  • Age 18 and older
  • 6 months of a documented diet and exercise program
  • Confirmed MASH diagnosis by FibroScan_VCTE, MRE, and liver_biopsy, fibrosis stage F2 to F3

Qualification pathways

You can qualify through any one of these.

MASH with moderate to advanced fibrosis

All of:

  • Patient is 18 years of age or older
  • Diagnosis of MASH (metabolic dysfunction-associated steatohepatitis), noncirrhotic, with moderate to advanced liver fibrosis consistent with stages F2 and F3
  • Fibrosis confirmed by a non-invasive test (NIT): VCTE, MRE, or historical liver biopsy
  • Actively engaged in comprehensive lifestyle modification plan (reduced calorie diet, increased physical activity, behavioral modifications)

Plus any one of:

  • Fibrosis confirmed by vibration-controlled transient elastography (VCTE)
  • Fibrosis confirmed by magnetic resonance elastography (MRE)
  • Fibrosis confirmed by historical liver biopsy

Documentation to bring

  • Documentation of diagnosis of MASH (metabolic dysfunction-associated steatohepatitis), previously known as noncirrhotic nonalcoholic steatohepatitis (NASH)
  • Documentation of moderate to advanced liver fibrosis consistent with stages F2 and F3
  • Results from one qualifying non-invasive test (NIT): vibration-controlled transient elastography (VCTE), magnetic resonance elastography (MRE), or historical liver biopsy
  • Confirmation that patient is 18 years of age or older
  • Physician attestation or documentation that member is actively engaged in comprehensive lifestyle modification plan (reduced calorie diet, increased physical activity, behavioral modifications)
  • For continuation: documentation of positive clinical response (MASH resolution with no worsening of liver fibrosis OR improvement in liver fibrosis)
  • For continuation: physician attestation of continued active engagement in comprehensive lifestyle modification plan
  • For continuation: documentation of FDA approved maintenance dose (1.7 or 2.4 mg subcutaneous injection)

Quantity limits

  • all strengths — 1-month supply (28 to 30 days); 75% of days must be exhausted before refill

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 12 months
  • To renew, the plan looks for Patient must have achieved or maintained a positive clinical response to therapy, such as MASH resolution with no worsening of liver fibrosis OR improvement in liver fibrosis. Patient must also be actively engaged in comprehensive lifestyle modification plan and be on FDA approved maintenance dose (1.7 or 2.4 mg subcutaneous injection) and staying on a maintenance dose of at least 1.7 mg.

Not covered when

  • Wegovy oral tablet and Wegovy HD are NOT FDA approved for MASH — subcutaneous Wegovy only
  • Cirrhotic NASH/MASH excluded (must be noncirrhotic)
  • Mail order pharmacy benefit excluded
  • Members with BCBSMA Focused Formulary: not a covered benefit effective 1/1/2026
  • Requests based exclusively on use of samples will not meet coverage criteria

Policy note: Policy specifies F2 and F3 fibrosis only (moderate to advanced, noncirrhotic). F4 (cirrhosis) is not covered under this indication. No lookback period specified for biopsy or imaging. FIB-4 and ELF test are not listed as acceptable confirmation methods — only VCTE, MRE, and historical liver biopsy qualify. MASH indication applies only to subcutaneous Wegovy (not oral or HD formulations).

Policy effective May 1, 2026 · verified June 2, 2026 · source: 572%20GLP-1%20and%20GLP-1%20-%20GIP%20Agonist%20Drugs%20for%20Anti-Obesity%20Management%20and%20Other%20Non-Obesity%20Conditions.pdf

Why Wegovy requests get denied by BCBS Massachusetts

Based on what this policy asks for. Fix these before the first submission.

  1. Wrong brand for the diagnosis. Wegovy and Ozempic are the same molecule with different approved uses; a request for Wegovy under a diagnosis that matches Ozempic is routinely denied.
  2. BMI not documented in the chart notes (or documented without a baseline weight and date).
  3. Qualifying weight-related condition not documented with its own diagnosis code.
  4. No documented diet and exercise program.
  5. Baseline weight wasn't recorded at the start, so the required weight loss can't be shown at renewal.

Frequently asked questions

Does BCBS Massachusetts cover Wegovy?
BCBS Massachusetts covers Wegovy for weight loss with prior authorization on Employer / Commercial Insurance.
What BMI do you need for Wegovy under BCBS Massachusetts?
For weight loss on Employer / Commercial Insurance plans, BCBS Massachusetts requires a BMI of 30 or higher, or 27 or higher with a qualifying weight-related condition.
How long does a Wegovy approval last with BCBS Massachusetts?
Initial approvals last 6 months, and renewals are granted in 12-month periods.
What does BCBS Massachusetts require to renew Wegovy?
At least 5% weight loss from the starting weight, Must meet ONE of: (a) documented weight loss of at least 5% of baseline body weight after first 16 weeks of treatment; OR (b) demonstrated continued weight loss; OR (c) maintaining plateau weight achieved with diet/exercise. Patient must also be adherent and tolerating recommended maintenance dose for at least 3 consecutive months, and continue with comprehensive weight management plan, and staying on a maintenance dose of at least 1.7 mg.
How current is this information?
This page reflects BCBS Massachusetts's written policy as of May 1, 2026, last verified against the source document on June 2, 2026.

Other medications under BCBS Massachusetts

Wegovy coverage under other plans

All insurance plans · All medications

This page summarizes BCBS Massachusetts's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.